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Background/Aims: There was the assumption that Crohn’s 
disease (CD) patients with perianal lesions might have dif-
ferent clinical courses compared to those without. However, 
quantifiable data comparing the long-term outcomes be-
tween the two groups are scarce. Methods: We retrospective-
ly reviewed 221 consecutive patients newly diagnosed with 
CD and registered at the IBD clinic of Severance Hospital, in 
Seoul, Korea, between January 1990 and October 2005. We 
compared patients with perianal CD (PCD) and non-perianal 
CD (NPCD) in terms of clinical outcomes over 10 years. Re-
sults: PCD progressed more frequently from inflammatory to 
complicated behavior than NPCD. Moreover, corticosteroids 
were prescribed in 102 patients with PCD and only 57 with 
NPCD (82.9% vs 58.2%, p<0.001), immunosuppressants 
in 89 and 42 (72.4% vs 42.9%, p<0.001), and anti-tumor 
necrosis factor α (TNF-α) in 37 and 12 (30.1% vs 12.2%, 
p=0.002). Cumulative hospitalization rates were 82.1% in 
PCD and 72.4% in NPCD (p=0.086), and surgical interven-
tion rates were 39.8% and 51.0%, respectively (p=0.097). 
Conclusions: Patients with PCD were more likely than those 
with NPCD to be administered corticosteroids, immunosup-
pressants, and anti-TNF-α. However, there is no significant 
difference in the cumulative rates of surgical interventions or 
hospitalizations. (Gut Liver 2018;12:297-305)
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INTRODUCTION
Crohn’s disease (CD) is a multifactorial chronic inflammatory 
bowel disease (IBD) that presents with unpredictable and vari-
ous clinical courses. The phenotypic heterogeneity of CD makes 
establishing a practically useful categorization difficult, which 
has led to diverse classification systems.1 In 2000, the Vienna 
classification system was introduced, and it has been widely 
used because of its simple framework that divides CD into 
subgroups according to age at diagnosis, disease location, and 
disease behavior, including inflammatory (B1), structuring (B2), 
and penetrating (B3) types.2 Earlier studies using the Vienna 
classification system found that disease behavior changes sig-
nificantly over time.3,4 They also demonstrated that perianal fis-
tulae occur independently of intestinal fistula in the penetrating 
type.5 Thus, in 2005, the Vienna classification was revised to the 
Montreal classification,6 which removed perianal disease from 
the penetrating type and allowed it to be added to any behavior 
to indicate simultaneous perianal lesions. However, it has been 
demonstrated that CD patients with perianal lesions might have 
different clinical courses and requirements for surgical or medi-
cal treatment than those without perianal lesions.7-9 Moreover, 
specific genetic factors related to perianal CD (PCD) have been 
investigated.10-12 
PCD can involve a variety of perianal lesions during the 
clinical course, ranging from asymptomatic and mild problems 
requiring only conservative treatment to severe situations that 
necessitate urgent surgical interventions, such as complex fis-
tula combined with abscess.13 It has also been reported that PCD 
itself has a more aggressive disease course that requires a more 
intensive treatment modality than non-perianal CD (NPCD).14,15 
Unfortunately, quantifiable data comparing the long-term 
outcomes of PCD and NPCD are scarce, although accurately 
understanding the distinction in clinical courses between them 
is critical in determining treatment modalities and accurately 
predicting clinical outcomes. Most research has dealt with PCD 
only as a predictive factor of clinical course.7,9,10,16-19 Accord-
ingly, our aim in this study was to identify the measurable dif-
ferences in long-term (more than 10 years) clinical outcomes 
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between CD patients with and without perianal lesions. 
MATERIALS AND METHODS
1. Study population
We retrospectively reviewed 236 consecutive patients newly 
diagnosed with CD and registered at the IBD clinic of Severance 
Hospital, a tertiary center in Seoul, South Korea, between Janu-
ary 1990 and October 2005. Patients were excluded from our 
analysis if they were followed up for less than 5 years at our 
hospital (n=13), were diagnosed simultaneously with another 
autoimmune disease (n=1), or visited our clinic while receiving 
treatment from another hospital (n=1). An established diagnosis 
of CD was based on a combination of conventional clinical, 
radiologic, endoscopic, and histopathologic findings.20 After 
confirming the diagnosis of CD, we evaluated the disease status 
of all patients at an outpatient clinic every 1 to 3 months. At 
each evaluation, we monitored the patient’s clinical symptoms 
and signs by both interview and questionnaire and also mea-
sured their complete blood cell counts and chemistry profiles. 
Colonoscopies or radiologic imaging studies such as computed 
tomography were performed at the physician’s discretion. In 
cases of complications such as perforation, bleeding, infection, 
or severely active disease flare-ups, patients were admitted and 
treated accordingly. This study was approved by the Institution-
al Review Board of Severance Hospital (IRB number: 4-2012-
0302).
2. Methods
We retrospectively analyzed the baseline demographic data 
(age at diagnosis, gender, and familial history of IBD) and medi-
cal data (disease location and behavior, extraintestinal symp-
toms, and previous history of appendectomy). In this study, 
perianal lesions were classified according to the American 
Gastroenterological Association medical position statement.21 
In our study, anal fistula, abscess, fissure, and stenosis (except 
for hemorrhoids and skin tags) were considered perianal lesions 
related to CD. First, we evaluated the characteristics and cumu-
lative occurrence rate of perianal lesions. To investigate differ-
ences in clinical outcomes between PCD and NPCD patients, we 
evaluated three categories: medical treatments (corticosteroids, 
immunosuppressants, such as azathioprine or 6-mercaptopurine, 
and anti-tumor necrosis factor  (TNF-) agents, such as inflix-
imab or adalimumab); surgical treatments (except for operations 
associated with perianal lesions); and hospitalization.
We followed the Montreal classification in determining the 
location (L1, small bowel; L2, colon; L3, small bowel and colon; 
and L4, upper gastrointestinal tract) and behavior (B1, inflam-
matory; B2, stenosis; B3, penetrating).22 The general treatment 
policy for CD in our center is based on a step-up approach.23 If 
CD patients are unresponsive to prior agents, we use higher step 
therapies as additions or replacements.
Fig. 1. Cumulative rate of perianal lesions in patients with Crohn’s 
disease.
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Table 1. Baseline Characteristics (n=221)
 Characteristic
Patients with 
perianal lesions 
(n=123)
Patients without 
perianal lesions 
(n=98)
p-value
Sex, male/female 78 (63.4)/
45 (36.6)
55 (56.1)/
43 (43.9)
0.271
Age, yr  23.4±7.8  30.3±13.5 <0.001
Follow-up period, mo 120 (60–246), 
130.1±42.2
121 (61–268), 
132.7±49.7
0.673
Last status 0.540
   Ongoing follow-up 97 (78.9) 71 (72.4)
   Loss of follow-up 24 (19.5) 25 (25.5)
   Death 2 (1.6) 2 (2.0)
Extraintestinal symptoms 0.083 
   With 32 (26.0) 16 (16.3)
   Without 91 (74.0) 82 (83.7)
Family history 0.106
   Yes 12 (9.8) 4 (4.1)
   No 111 (90.2) 94 (95.9)
Previous appendectomy 0.096
   Yes  16 (13.0) 21 (21.4)
   No 107 (87.0) 77 (78.6)
Data are presented as number (%), mean±SD, or median (range).
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3. Statistics 
Continuous variables are presented as the mean±standard 
deviation or median (range) and compared using two-sample t-
tests. Categorical variables were compared by chi-square tests 
or Fisher exact tests. The Kaplan-Meier method was used to 
generate the curve, and a log-rank comparison was performed 
to compare the cumulative probabilities that PCD and NPCD pa-
tients would receive specific medical treatments (corticosteroids, 
immunosuppressants, and anti-TNF- agents) and surgical 
treatments. p-values less than 0.05 were considered significant. 
All statistical analyses were performed using the statistical soft-
ware package SPSS version 12.0 for Windows (SPSS Inc., Chi-
cago, IL, USA). 
RESULTS
1. Characteristics and clinical course of disease
We included 221 CD patients in the study. Of these, 123 pa-
tients (55.7%) eventually developed perianal lesions. PCD was 
identified in 82 patients (37.1%) at the time of diagnosis and 
in 41 patients (18.6%) thereafter. The perianal lesions included 
103 (83.7%) patients with fistula, 47 (38.2%) with abscess, 25 
(20.3%) with fissure, and 16 (13.0%) with stenosis. Eleven cases 
had only fissure, six cases had only stenosis, and one case had 
all four types of perianal lesions. The cumulative occurrence 
rates of perianal lesion were 37.2% at diagnosis, 38.9% after 1 
year, 43% after 3 years, 45.2% after 5 years, and 53.0% after 10 
years (Fig. 1). Of 221 CD patients, 37.2% (82/221) had perianal 
lesion at diagnosis. In other words, among 123 PCD patients, 
approximately two-thirds of patients (82/123) presented initially 
perianal lesions. The baseline characteristics of PCD and NPCD 
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Fig. 2. Tendency of behavior distribution over time between (A) perianal Crohn’s disease (CD) and (B) non-perianal CD.
Table 2. Comparison of the Clinical Outcomes with Medication Use
Details of outcomes
Patients with 
perianal lesions 
(n=123)
Patients without 
perianal lesions 
(n=98)
p-value
Steroid use 102 (82.9) 57 (58.2) <0.001
    No. of flare-up events 
      requiring steroid 
      administration
3.3±2.3 2.4±1.9  0.015
    Total duration of steroid 
      administration, day
372.2±577.2 226.7±205.8  0.068
    Days of steroid administration 
      per flare-up 
108.4±114.5 94.6±45.5  0.383
Immunosuppressants use  89 (72.4) 42 (42.9) <0.001
    Duration from first steroid 
      to first immunosuppressant 
      administration, mo
26.0±30.7 28.6±41.8  0.700
Anti-TNF- therapy use  37 (30.1) 12 (12.2)  0.002
    Duration from first 
      corticosteroid to first 
      anti-TNF- administration, 
      mo
59.2±40.1 64.9±50.5  0.689
    Duration from first 
      immunosuppressant to 
      first anti-TNF- 
      administration, mo
40.6±36.8 40.2±39.5  0.971
Data are presented as number (%) or mean±SD.
TNF-, tumor necrosis factor .
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patients are compared in Table 1. The mean age at diagnosis 
was significantly younger in PCD than in NPCD (23.4±7.8 vs 
30.3±13.5, p<0.001), but there was no significant difference 
in gender (male, 63.4% vs 56.1%, p=0.271), mean duration of 
follow-up (130.1±42.2 months vs 132.7±49.7 months, p=0.673), 
extraintestinal symptoms (26.0% vs 16.3%, p=0.083), or family 
history of IBD (9.8% vs 4.1%, p=0.106). At the time of diagno-
sis, 26 PCD patients (21.1%) had disease located in L1, 25 (20.3%) 
in L2, 70 (56.9%) in L3, and two (1.6%) in L4, whereas 32 NPCD 
patients (32.7%) had disease located in L1, 26 (26.5%) in L2, 40 
(40.8%) in L3, and none in L4. Disease behavior in PCD at diag-
nosis was inflammatory (B1) type in 70 patients (56.9%), struc-
turing (B2) in 31 patients (25.2%), and penetrating (B3) in 22 
patients (17.9%). Fifty-eight (59.2%) of the NPCD patients were 
diagnosed with B1 type behavior, 21 (21.4%) with B2, and 19 
(19.4%) with B3. Fig. 2 shows the trends of change in behavior 
distribution during the course of PCD and NPCD. Twenty years 
after diagnosis, PCD exhibited type B1 behavior in 26.8% of 
cases, B2 in 15.4%, and B3 in 57.5%, whereas the NPCD behav-
iors were show in 39.8%, 16.3%, and 43.9%, respectively.
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2. Comparisons of treatment course
Table 2 shows the comparison of overall medication pre-
scriptions for PCD and NPCD. Systemic corticosteroids were 
prescribed for 102 PCD patients (82.9%) and 57 NPCD patients 
(58.2%) at diagnosis or during the follow-up period. The cumu-
lative probabilities of steroid administration were 41.5% after 
1 year, 55.3% after 3 years, 70.7% after 5 years, 82.1% after 
10 years, and 82.9% after 15 years among PCD patients and 
29.6%, 38.8%, 45.9%, 55.1%, and 58.2%, respectively, among 
NPCD patients (Fig. 3). Details of the clinical outcomes regard-
ing corticosteroid use are given in Table 2. The mean frequency 
of disease flare-up events requiring steroid administration was 
3.3±2.3 in PCD patients and 2.4±1.9 in NPCD (p=0.015). The 
mean total duration of steroid administration was 372.2±577.2 
days in PCD and 226.7±205.8 days in NPCD (p=0.068), and the 
mean days of steroid administration per event of disease flare-
up was 108.4±114.5 and 94.6±45.5 days, respectively (p=0.383). 
Immunosuppressants (azathioprine or 6-mercaptopurine) were 
administered to 89 patients (72.4%) with PCD and 57 (58.2%) 
with NPCD. The cumulative probabilities of immunosuppressant 
use were 10.6% after 1 year, 31.8% after 3 years, 45.5% after 
5 years, 67.5% after 10 years, and 72.4% after 15 years among 
PCD patients and 7.1%, 18.4%, 28.6%, 38.8%, and 41.8%, re-
spectively, among NPCD patients (Fig. 3). Details of clinical 
outcomes regarding immunosuppressant use are described in 
Table 2. The mean duration from corticosteroids to first im-
munosuppressant administration was 26.0±30.7 months in PCD 
and 28.6±41.8 months in NPCD (p=0.700). 
Anti-TNF- agents were used in 37 patients (30.1%) in PCD 
and 12 (12.2%) in NPCD (p<0.001). The cumulative frequency 
of anti-TNF- use is shown in Fig. 3. Anti-TNF- was used in 
no patients after 1 year, 4.9% after 3 years, 10.6% after 5 years, 
23.6% after 10 years, and 29.3% after 15 years in PCD and 
in no patients, 1.0%, 2.0%, 8.2%, and 10.2%, respectively, in 
NPCD. Details of clinical outcomes regarding anti-TNF- agents 
Table 3. Detailed Clinical Outcomes of the Surgical Treatments and Hospitalizations
Variables for clinical outcomes
Patients with perianal lesions 
(n=123)
Patients without perianal lesions 
(n=98)
p-value
Surgical treatment 0.097
   Yes/no 49 (39.8)/74 (60.2) 50 (51.0)/48 (49.0)
No. of surgical interventions 0.047
   1 27 (55.1) 36 (72.0)
   2 12 (24.5) 10 (20.0)
   >2 10 (20.4) 4 (8.0)
Reason for surgery 0.025
   Intestinal fistula or abscess 49 (52.7) 24 (33.3) 
   Obstruction or stricture 12 (12.9) 14 (19.4)
   Perforation 19 (20.4) 13 (18.1)
   Pain due to uncontrolled lesion 3 (3.2) 10 (13.9)
   Other 10 (10.8) 11 (15.3)
Types of operation 0.022
   Small bowel resection 33 (35.5) 30 (44.8)
   Right hemicolectomy 22 (23.7) 22 (32.8)
   Ileocecectomy 9 (9.7) 8 (11.9)
   Other colectomy 27 (29.0) 5 (7.5)
   Primary repair 2 (2.2) 2 (3.0)
Hospitalization 0.086
   Yes/no 101 (82.1)/22 (17.9) 71 (72.4)/27 (27.6)
Among hospitalized patients (n=172) 101 71
   No. of hospitalizations 4.6±4.8 3.2±2.9 0.016
   Total days of hospitalization, day 54.9±70.9 42.4±58.6 0.226
   Days per hospitalization, day 11.8±11.2 13.9±11.6 0.222
   No. of hospitalizations due to perianal lesions 0.8±1.3 - -
   Total days of hospitalization due to perianal lesions, day 5.3±12.2 - -
Data are presented as number (%) or mean±SD.
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are shown in Table 2. The mean duration from first corticoste-
roids to first anti-TNF- administration was 59.2±40.1 months 
in PCD and 64.9±50.5 months in NPCD (p=0.689). The mean 
duration from first immunosuppressant to first anti-TNF- ad-
ministration was 40.6±36.8 and 40.2±39.5 months in PCD and 
NPCD, respectively (p=0.971). 
Forty-nine PCD patients (39.8%) and 50 NPCD patients 
(51.0%) underwent surgical treatment (p=0.097). Details are 
presented in Table 3. PCD patients underwent intestinal resec-
tion more than three times more frequently than NPCD patients 
(20.4% vs 8.0%, p=0.047) and had surgery more often for 
intestinal fistula or abscess, not counting procedures for anal 
abscesses (56.3% vs 24.7%, p=0.025). The cumulative rates of 
surgical intervention are shown in Fig. 4. Although surgical 
intervention was performed more frequently in NPCD patients 
than in PCD within 1 year of diagnosis, this modality was ap-
plied more frequently to PCD patients than NPCD patients 
thereafter. Ultimately, there was no significant difference in the 
proportion of patients receiving surgical intervention between 
the two groups (39.8% vs 51.0%, p=0.097). 
Hospitalization occurred at least once in 101 patients (82.1%) 
with PCD and 71 (72.4%) with NPCD (p=0.086). Details associ-
ated with hospitalization are summarized in Table 3. The mean 
frequency of hospitalization was higher in PCD than in NPCD 
(4.6±4.8 vs 3.2±2.9, p=0.016). There was no significant differ-
ence in total days of hospitalization or days per hospitaliza-
tion between the two groups. Of patients with PCD, the mean 
frequency and total days of hospitalization related to perianal 
lesion were 0.8±1.3 and 5.3±12.2, respectively. The cumulative 
rates of hospitalization due to CD itself (leaving out cases di-
rectly associated with perianal lesions) are shown in Fig. 4.
DISCUSSION
In the present study, we first demonstrated the detailed clini-
cal patterns and long-term prognoses of PCD and NPCD in a 
Korean population across more than 10 years. Our study showed 
that perianal lesion occurred in 55.7% of CD patients (123/221), 
which makes it more prevalent in our study than in earlier 
Western studies. Previous studies have noted that race might 
be a factor for occurrence of perianal disease.3,24 According to 
the literature, 14% to 37% of Western CD patients and 37% to 
50% of Asian CD patients experienced perianal disease.15,16,24-29 
Our results are thus consistent with previous findings that PCD 
is more common in Asian CD patients than in Western ones. 
Our data also revealed that perianal lesions were present before 
or at the diagnosis of CD in 37.2% of patients, and that the cu-
mulative rate of PCD 13 years after diagnosis was 55.7%. Our 
data showed that, in about two-thirds of patients, PCD was the 
initial disease presentation, corresponding to an earlier study 
that found that 46% of PCD developed before diagnosis.15 We 
found no significant difference in several factors influencing 
the development of perianal disease (gender, extraintestinal 
symptoms, family history of IBD, and previous history of ap-
pendectomy), but age was an influential factor. Some of these 
findings were consistent with previous ones (gender15,24 and 
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family history of IBD30). CD accompanied by extraintestinal 
symptoms was more prevalent in PCD than in NPCD (26.0% vs 
16.3%), but that difference was not significant (p=0.083) in our 
data, which is dissimilar to the findings of a previous study.18 It 
was previously reported that younger age at diagnosis was as-
sociated with PCD.3,10,24 Eglinton et al.10 found that the mean age 
at diagnosis was 8.1 years younger for PCD (30.0 years) than 
NPCD (38.1 years), while we found a difference of 6.9 years (23.4 
years vs 30.3 years).
Previous studies of the relationship between CD behavior 
and perianal disease yielded varying results. Some studies re-
ported that perianal disease represents a factor for complicated 
behavior such as penetrating and structuring disease.10,24 Others 
found that PCD and complicated types had no association.31,32 
Our longitudinal observation demonstrated that the disease 
behavior at diagnosis did not differ significantly between PCD 
and NPCD. However, patients with PCD progressed more rapidly 
from inflammatory to complicated behavior over the course of 
the disease than those with NPCD. After 20 years, there was a 
pronounced difference in terms of disease behavior between the 
two groups. The proportions of B1, B2, and B3 in PCD changed 
from 57%, 25%, and 18%, respectively, at diagnosis to 27%, 
15%, and 58% after 20 years, whereas those same proportions 
in NPCD changed from 59%, 21%, and 19% at diagnosis to 
40%, 16%, and 44% 20 years later. In terms of disease location, 
we also found that colonic involvement was more common in 
PCD (79%) than in NPCD (67%), consistent with earlier pub-
lished data, reinforcing the theory that PCD occurs less often 
in ileal CD and more often in CD that involves the colon.15,33 In 
contrast to disease behavior, which changed dramatically, dis-
ease location was relatively stable and not significantly differ-
ent between the disease types in the present study: only 13 PCD 
cases and 12 NPCD cases progressed to the ileocolonic category, 
similar to reports in previous studies.4,7,28
It has been shown that patients with PCD experience a more 
severe luminal disease course and often require multiple surgi-
cal interventions and intensive medical therapies.7,9,10,17,19,34 We 
observed that patients with PCD had a significantly higher cu-
mulative rate of administration of all medicines: corticosteroids, 
immunosuppressants such as azathioprine, and anti-TNF- 
agents. The overall odds ratio in our study was 3.49 for cortico-
steroids, 3.49 for immunosuppressants, and 3.08 for anti-TNF- 
agents. We found several notable points between PCD and 
NPCD in medical treatment. In the use of corticosteroids, even 
though disease flare-up events occurred more frequently in PCD 
than NPCD (3.3 vs 2.4, p=0.015), the difference in the number of 
days of corticosteroid administration per flare-up event was not 
significant (108 days vs 95 days, p=0.383). Thus, PCD might not 
be a predictive factor for corticosteroid dependency even though 
more patients with PCD took this drug. In immunosuppressant 
use, we found no difference in duration from first corticosteroid 
to first immunosuppressant use between PCD and NPCD (26.0 
months vs 28.6 months, p=0.700). In anti-TNF- use, there was 
no significant difference in either duration from first cortico-
steroids to first infliximab administration (59.2 months vs 64.9 
months, p=0.689) or duration from first immunosuppressants 
to first infliximab administration (40.6 months vs 40.2 months, 
p=0.971). In other words, the step-up approach, a strategy for 
treating CD, did not progress more rapidly but only occurred 
more frequently in PCD than in NPCD.
Although there was no significant difference in the propor-
tion of patients undergoing surgical treatment (not counting 
perianal-related operations) between PCD and NPCD in our 
results (40% vs 51%, p=0.097), the cumulative frequency of sur-
gery was higher in NPCD than in PCD, especially within 1 year. 
Traditionally, PCD has been considered to carry a risk of bowel 
resection.15 Even though our finding about the early operation 
rate might be discordant with previous reports, we did find that 
multiple surgeries were performed more frequently in patients 
with PCD, similar to the findings of other studies.18,35 We assume 
that the higher early surgical rate in NPCD patients resulted 
from the following two factors. First, a substantial portion of 
our patients with critical conditions presented with abdominal 
pain from intestinal stricture that went unrecognized before 
CD diagnosis, probably because CD is uncommon, so primary 
clinicians and patients were insufficiently aware of it until an 
emergency situation arose. Second, patients whose CD involves 
the terminal ileum are known to have a higher risk for needing 
surgery.35,36 Given that, in our study population, NPCD patients 
had a much greater proportion of isolated ileal involvement, 
especially in the terminal ileum, than PCD patients, the higher 
early rate of bowel resection in NPCD could be also explained 
by disease location. 
The present study has several limitations. First, many patients 
in our cohort were treated in the era before anti-TNF- therapy 
became available. Thus, it was difficult to evaluate how the dis-
ease course was ameliorated by the role of anti-TNF- therapy. 
Second, the retrospective nature and single-center study design 
could be vulnerable to selection bias. Third, there was no data 
dealing with clinical manifestation according to subtype of peri-
anal lesion or perianal fistula (simple vs complex). Despite these 
limitations, our study has some strengths. We longitudinally 
monitored more than 10 years of quantifiable measures on 
disease course and detailed variables for multidisciplinary treat-
ment modalities in comparing PCD and NPCD.
In conclusion, we demonstrated that patients with PCD were 
associated with younger age at diagnosis and more considerable 
changes in disease behavior to the structuring or penetrating 
types than patients with NPCD. In term of medical treatment, 
PCD patients were more likely to need corticosteroids, immu-
nosuppressants, and anti-TNF- agents than NPCD patients. 
Whereas there were relatively similar rates in surgical interven-
tions and hospitalizations between PCD and NPCD. These find-
ings could help clinicians and researchers understand PCD as a 
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distinct disease phenotype and pursue better targeted treatments 
for PCD patients.
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